cyc 202 has been researched along with ruboxistaurin in 6 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (ruboxistaurin) | Trials (ruboxistaurin) | Recent Studies (post-2010) (ruboxistaurin) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 203 | 29 | 56 |
| Protein | Taxonomy | cyc 202 (IC50) | ruboxistaurin (IC50) |
|---|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | 0.6484 | |
| Protein kinase C gamma type | Homo sapiens (human) | 0.3 | |
| Protein kinase C alpha type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C beta type | Homo sapiens (human) | 0.0054 | |
| Protein kinase C delta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C epsilon type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C zeta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 0.2 | |
| Protein kinase C alpha type | Homo sapiens (human) | 0.36 | |
| Protein kinase C eta type | Homo sapiens (human) | 0.052 | |
| Protein kinase C gamma type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C beta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C epsilon type | Homo sapiens (human) | 0.6 | |
| Protein kinase C delta type | Homo sapiens (human) | 0.25 | |
| Protein kinase C eta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Homeodomain-interacting protein kinase 1 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 4 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 2 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 3 | Homo sapiens (human) | 0.1 | |
| Protein kinase C theta type | Rattus norvegicus (Norway rat) | 0.32 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Russu, WA; Shallal, HM | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
6 other study(ies) available for cyc 202 and ruboxistaurin
| Article | Year |
|---|---|
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |